The post Shiba Inu Price Drops 4% as Exchange Netflow Signals Selling Pressure appeared on BitcoinEthereumNews.com. Shiba Inu has entered a correction phase afterThe post Shiba Inu Price Drops 4% as Exchange Netflow Signals Selling Pressure appeared on BitcoinEthereumNews.com. Shiba Inu has entered a correction phase after

Shiba Inu Price Drops 4% as Exchange Netflow Signals Selling Pressure

Shiba Inu has entered a correction phase after experiencing significant gains in the previous trading session. The meme coin has spent the entire day trading in negative territory. At the time of writing, SHIB trades at around $0.00000838, indicating a 4.09% decline in the token’s value over the past 24 hours.

SHIB’s price action over the past 24 hours (Source: CoinCodex)

The downward movement appears linked to waning demand from investors. Trading activity has slowed considerably compared to the bullish momentum witnessed just one day earlier. Market participants are now closely monitoring on-chain metrics for signals of where the price might head next.

Exchange netflow data reveals a concerning trend for SHIB holders. The metric has increased by 1.54% during the last 24-hour period. This uptick indicates that more tokens are flowing onto exchanges than leaving them. Such movements typically precede selling activity.

Rising Exchange Deposits Point to Bearish Sentiment

Cryptoquant data shows that exchange netflow currently sits at over 52 billion SHIB tokens. This figure represents the gap between deposits and withdrawals across all trading platforms. The positive netflow means sellers have moved significantly more tokens to exchanges than buyers have removed.

The increase spans major cryptocurrency platforms including Binance and Coinbase. These venues handle the majority of Shiba Inu trading volume globally. When tokens accumulate on exchanges, supply available for sale expands. This dynamic creates downward pressure on prices.

The previous day’s rally provided an opportunity for early investors to lock in gains. Whale wallets appear to be among those reducing positions based on transaction patterns.

The timing of these deposits suggests strategic selling. Traders likely waited for the price spike to maximize returns before moving tokens to exchanges. This pattern is common during volatile market conditions when assets experience rapid price swings.

Investor Confidence Remains Despite Short-Term Weakness

Not all market participants view the current situation negatively. Some investors maintain optimistic outlooks for Shiba Inu’s medium-term prospects. They argue that selling pressure will eventually exhaust itself as supply diminishes.

The theory rests on the assumption that current holders are simply rotating profits. Once these sellers exit their positions, fresh demand could emerge at lower price levels. This cyclical pattern has played out multiple times in SHIB’s trading history.

Source: https://coinpaper.com/13794/shiba-inu-price-decline-continues-as-exchange-netflow-signals-profit-taking-activity

Market Opportunity
BitShiba Logo
BitShiba Price(SHIBA)
$0.0000000004515
$0.0000000004515$0.0000000004515
-0.08%
USD
BitShiba (SHIBA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26